New Healthcare market report from Business Monitor International: "Iraq Pharmaceuticals & Healthcare Report Q2 2013"

Boston, MA -- (SBWire) -- 05/22/2013 --BMI View: Iraq's healthcare and pharmaceuticals market has suffered from a lack of investment and the impact of war - much of the infrastructure is outdated; hospitals, clinics and pharmacies lack trained personnel; and the health insurance sector is immature and can offer the government little in terms of income. Other issues, such as continued security risks, also remain, holding back development and deterring multinationals. The government is taking steps to modernise healthcare facilities, however, and a combination of agreements with other governments (attracted by Iraq's natural resources), NGOs and public spending is funding new developments. There are several new hospital projects in the pipeline, and the government has also expressed plans to restructure and privatise state-owned enterprises - which has caught the interest of potential investors. Iraq's regulatory framework also needs strengthening, as, in its current state, there is little distinction between prescription and OTC drugs, while counterfeit medicines are rife.

View Full Report Details and Table of Contents

Headline Expenditure Projections

- Pharmaceuticals: IQD1,328bn (US$1.14mn) in 2012 to IQD1,545bn (US$1.33bn) in 2013; +16.4% in local currency and +16.7% in US dollar terms. Forecast lowered from Q113 on account of new import data.
- Healthcare: IQD11,255bn (US$9.66bn) in 2012 to IQD13,311bn (US$11.45bn) in 2013; +18.3% in local currency and +18.6% in US dollar terms. Forecast increased from Q113 because of an expected rise in healthcare capital expenditure.

Risk/Reward Rating: Iraq's Pharmaceutical Risk/Reward Rating (RRR) score for Q213 is unchanged from the previous quarter. This is also the case for all other countries in BMI's proprietary system that ranks pharmaceutical markets according to attractiveness to multinational drugmakers. A minor re-weighting of one of the RRR components is being implemented to improve the tool, and the adjusted scores for all markets will be published in the Q313 updates of the Pharmaceuticals & Healthcare reports. Iraq has a RRR score of 46.7 out of 100, making it the 13th most attractive pharmaceutical market in the Middle East and African region.

Key Trends And Developments

In February 2013, Iraq's government announced that construction work had begun on a US$350mn medical city in Baghdad. Built on the site of the former Rasheed hospital, the medical city will have 1,200 beds and add new specialisations, such as neurological disorders, to Iraq's healthcare sector.

Egypt and Iraq agreed in March 2013 to form a joint business council that will see increased economic ties between the two countries. Iraq is keen for Egyptian firms to invest in major infrastructure projects in the country - including the construction of hospitals.

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Healthcare research reports at Fast Market Research

You may also be interested in these related reports:

- Malaysia Pharmaceuticals & Healthcare Report Q2 2013
- Vietnam Pharmaceuticals & Healthcare Report Q2 2013
- Romania Pharmaceuticals & Healthcare Report Q2 2013
- Nigeria Pharmaceuticals & Healthcare Report Q3 2013
- Ghana Pharmaceuticals & Healthcare Report Q2 2013
- Croatia Pharmaceuticals & Healthcare Report Q2 2013
- Kuwait Pharmaceuticals & Healthcare Report Q2 2013
- Italy Pharmaceuticals & Healthcare Report Q2 2013
- Ukraine Pharmaceuticals & Healthcare Report Q2 2013
- Poland Pharmaceuticals & Healthcare Report Q2 2013